IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A REAL-LIFE, RETROSPECTIVE, MULTICENTER TRIAL ON BEHALF OF THE "RTL" (REGIONAL TUSCAN LYMPHOMA NETWORK)

Emanuele Cencini,Bianca Mecacci,Francesca Morelli,Francesco Ghio,Ilaria Romano,Silvia Birtolo,Federico Simonetti,Valentina Zoi,Sabrina Moretti,Emanuela Sant'Antonio,Annarosa Cuccaro,Simone Santini,Sofia Kovalchuk,Sara Galimberti,Monica Bocchia,Alberto Fabbri

HAEMATOLOGICA（2021）

引用 1|浏览23

暂无评分

摘要

In this real-life setting ibrutinib treatment prolonged survival in R/R MCL patients, without unexpected adverse events. Patients receiving ibrutinib as 2 line regimen had the most favorable outcome.

查看译文

关键词

Mantle cell lymphoma,ibrutinib,prognosis,safety,survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要